PF477 CHANGES IN OVERALL SURVIVAL OF HODGKIN'S LYMPHOMA PATIENTS IN UKRAINIAN POPULATION DURING LAST DECADES
Authors: K. Filonenko, I. Kriachok, I. Tytorenko, Z. Fedorenko, L. Koutsenko
Journal: HemaSphere (2019)

Background: The overall survival (OS) in patients with Hodgkin's Lymphoma (HL) have changed dramatically over the last few decades. Aims: We analysed data from Ukrainian National Cancer Registry (UNCR) to understand the dynamic of OS in HL patients in our population. Methods: We performed retrospective analysis of the epidemiological data from UNCR in patients diagnosed with HL since 1996 to 2010 (all ages). The available baseline characteristics were age at diagnosis, gender, histological subtype, stage, treatment type (radiotherapy (RT), chemotherapy (CX), combined treatment (CT) or no treatment). The patients were divided into 3 groups based on the date of diagnosis of HL: patients in group 1 were diagnosed between 1996 and 2000, in group 2 – between 2001 and 2005, and in group 3 – between 2006 and 2010. Results: We’ve extracted the data of 17457 patients with the age at the diagnosis 1–98 years old (median 31 years old). There were 8581 males and 8876 females. The stage wasn’t known in the majority of cases (51.2%). All histological subtypes of HL were presented: classical HL nodular sclerosis in 15.7%, mixed cellularity – in 17.2%, lymphocyte rich – in, 5.4%, lymphocyte depleted – in 5.0%, nodular lymphocyte‐predominant Hodgkin lymphoma – in 2.8%, and unknown subtype – in 53.9%. Treatment was in 85.4% of cases. RT only received 1.7% of patients, 39.8% – CX only and 43.9% – CT. There were 5735 patients in group 1, 5736 patients – in group 2 and 5986 patients – in group 3. Groups were similar by gender and histological subtypes. Older patients were in the group 3 (p = 0.01). The proportion of patients with early stages was significantly higher in the group 1 (37.7%) comparing to group 2 (28.4%, p &lt; 0.001) and group 3 (27.2%, p &lt; 0.05). The number of patients treated wuth RT alone decreased each 5 years (from 2.1% in the group 1 to 1.4% in the group 3; p &lt; 0.000). The proportion of patients treated with CT was higher in the group 3 (47.8%) comparing to the group 1 (42.7%) and group 2 (42.4%), p &lt; 0.000. Therefore, the number of irradiated patients (alone or in CT) was higher in group 3 (47.8%) compared to group 1 (44.8%) and group 2 (44.1%) p &lt; 0.000. 5‐year OS in CX group was 79.0%, in CT group – 75.3%, in RT group – 76.7% and in no treatment group 66.0% ( p &lt; 0.000). The 5‐year OS was 76.4% in the general group, 59.0% ‐ in group 1, 83.7% ‐ in group 2, and 89.6% ‐ in group 3 ( p &lt; 0.000). Gender and histological subtype didn’t influence the OS in the general group of patients. Stage of the disease significantly influenced on 5‐year OS ( p &lt; 0.000). 5‐year OS was 79.0% in patients treated with RT (alone or in CT) and 73.5% in non‐irradiated patients. In the group 3 stage of the disease didn’t influence on OS (p = 0.146). 5‐year OS was 93.8% in patients treated with RT (alone or in CT) and 85.1% in non‐irradiated patients. 5‐year OS in CX group was 94.1%, in CT group – 88.2%, in RT group – 87.9% and in no treatment group 83.7% ( p &lt; 0.000). Summary/Conclusion: The continuos improvement in OS in patients with HL in Ukraine was observed through the 15 analysed years. Stage, treatment type and presence of RT significantly influenced on survival in general group of patients. There was no influence of the disease stage on OS in patients diagnosed in 2006–2010. OS was better through all time periods in patients, who received RT.